X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1760) 1760
Publication (136) 136
Newsletter (100) 100
Book Review (27) 27
Book Chapter (22) 22
Newspaper Article (16) 16
Book / eBook (8) 8
Magazine Article (7) 7
Government Document (4) 4
Conference Proceeding (2) 2
Dissertation (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1346) 1346
male (859) 859
female (766) 766
index medicus (736) 736
carbamates - adverse effects (602) 602
middle aged (572) 572
carbamates (566) 566
adult (545) 545
carbamates - therapeutic use (518) 518
animals (419) 419
aged (410) 410
pharmacology & pharmacy (354) 354
carbamates - administration & dosage (311) 311
treatment outcome (262) 262
drug therapy, combination (235) 235
pesticides (219) 219
toxicology (207) 207
carbamates - pharmacology (206) 206
dose-response relationship, drug (185) 185
sulfonamides - adverse effects (185) 185
analysis (164) 164
adolescent (158) 158
hiv infections - drug therapy (158) 158
sulfonamides - therapeutic use (157) 157
research (155) 155
carbamates - pharmacokinetics (154) 154
oncology (138) 138
drug therapy (136) 136
rats (136) 136
deoxycytidine - analogs & derivatives (132) 132
drug interactions (126) 126
environmental sciences (125) 125
toxicity (124) 124
capecitabine (121) 121
insecticides (121) 121
piperidines - therapeutic use (120) 120
sulfonamides - administration & dosage (118) 118
antiviral agents - therapeutic use (112) 112
pharmacokinetics (112) 112
double-blind method (110) 110
health aspects (110) 110
administration, oral (109) 109
clinical trials as topic (109) 109
hepatitis c, chronic - drug therapy (109) 109
phenylcarbamates (109) 109
mice (108) 108
drug administration schedule (106) 106
efficacy (105) 105
genotype (103) 103
diabetes mellitus, type 2 - drug therapy (102) 102
rivastigmine (102) 102
young adult (102) 102
piperidines - adverse effects (101) 101
therapy (101) 101
aged, 80 and over (100) 100
hepacivirus - genetics (100) 100
ritonavir - adverse effects (98) 98
safety (98) 98
fluorouracil - analogs & derivatives (97) 97
oral fluoropyrimidine carbamate (97) 97
hiv protease inhibitors - adverse effects (94) 94
ritonavir (93) 93
double-blind (92) 92
antiviral agents - adverse effects (91) 91
deoxycytidine - adverse effects (91) 91
ritonavir - administration & dosage (90) 90
time factors (90) 90
drug combinations (89) 89
medicine, general & internal (89) 89
ritonavir - therapeutic use (87) 87
deoxycytidine - administration & dosage (86) 86
hypoglycemic agents - therapeutic use (86) 86
infectious diseases (86) 86
public, environmental & occupational health (86) 86
clinical neurology (85) 85
care and treatment (84) 84
alzheimer disease - drug therapy (83) 83
anti-hiv agents - therapeutic use (82) 82
cholinesterase inhibitors - therapeutic use (82) 82
anti-hiv agents - adverse effects (76) 76
hepatitis c (76) 76
risk assessment (76) 76
medicine & public health (75) 75
uracil - analogs & derivatives (75) 75
exposure (73) 73
sulfonamides - pharmacokinetics (73) 73
hypoglycemic agents - adverse effects (72) 72
ribavirin (71) 71
cancer (70) 70
carbamate (70) 70
cholinesterase inhibitors - adverse effects (70) 70
hepatitis c virus (70) 70
insecticides - adverse effects (70) 70
hiv protease inhibitors - therapeutic use (69) 69
antiviral agents (68) 68
repaglinide (68) 68
risk factors (68) 68
deoxycytidine - therapeutic use (67) 67
antiviral agents - administration & dosage (66) 66
dosage and administration (66) 66
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1806) 1806
German (35) 35
French (21) 21
Russian (17) 17
Spanish (12) 12
Japanese (10) 10
Dutch (5) 5
Polish (4) 4
Portuguese (3) 3
Chinese (2) 2
Hungarian (2) 2
Italian (2) 2
Croatian (1) 1
Danish (1) 1
Indonesian (1) 1
Norwegian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA Dermatology, ISSN 2168-6068, 09/2014, Volume 150, Issue 9, pp. 984 - 989
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
OBJECTIVENew potent direct-acting antiviral (DAA) regimens against hepatitis C virus have been approved in recent years. However, information about the rate of... 
ribavirin | ledipasvir and sofosbuvir | hepatitis C virus | ombitasvir and dasabuvir | genotype 1 | adverse events | randomized | direct-acting antivirals | paritaprevir | ACUTE LIVER-FAILURE | VIRUS-INFECTION | SOFOSBUVIR | HCV INFECTION | REAL-WORLD EFFECTIVENESS | SUSTAINED VIROLOGICAL RESPONSE | DASABUVIR | GENOTYPE 1B CIRRHOSIS | RITONAVIR-BOOSTED PARITAPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Fatigue - chemically induced | Drug Therapy, Combination - adverse effects | Ritonavir - adverse effects | Adult | Female | Fluorenes - adverse effects | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Headache - chemically induced | Antiviral Agents - therapeutic use | Anemia - chemically induced | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Uracil - adverse effects | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Viral Load - drug effects | Uracil - analogs & derivatives | Drugs | Antiviral agents | Complications and side effects | Treatment outcome | Usage | Analysis | Adverse and side effects | Hepatitis C | Drug therapy | Risk factors
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
Journal Article
The Oncologist, ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article